1. WickramasuriyaGAW (1935) Some observations on malaria occuring in association with pregnancy. With special reference to the transplacental passage of parasites from the maternal to the foetal circulation. Br J Obstet Gynaecol 42: 816–834.
2. McGregorIA (1984) Epidemiology, malaria and pregnancy. Am J Trop Med Hyg 33: 517–525.
3. SteketeeRW, WirimaJJ, BlolandPB, ChilimaB, MerminJH, et al. (1996) Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg55 (suppl 1)42–49.
4. ter KuileFO, PariseME, VerhoeffFH, UdhayakumarV, NewmanRD, et al. (2004) The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71: 41–54.
5. GarnerP, BrabinB (1994) A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull World Health Organ 72: 89–99.
6. World Health Organization (1986) WHO Expert Committee on Malaria 18th report; WHO Technical Series No. 735: p58. Geneva: WHO.
7. BrabinBJ, GinnyM, AlpersM, BrabinL, EggelteT, et al. (1990) Failure of chloroquine prophylaxis for falciparum malaria in pregnant women in Madang, Papua New Guinea. Ann Trop Med Parasitol 84: 1–9.
8. SteketeeRW, WirimaJJ, SlutskerL, HeymannDL, BremanJG (1996) The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. Am J Trop Med Hyg 55 (suppl 1)2–7.
9. World Health Organization (2012) Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine- Pyrimethamine (IPTp-SP). Updated WHO Policy Recommendation. Geneva: WHO. Available: http://www.who.int/malaria/iptp_sp_updated_policy_recommendation_en_102012.pdf. Accessed 15 August 2014.
10. SchultzLJ, SteketeeRW, MachesoA, KazembeP, ChitsuloL, et al. (1994) The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 51: 515–522.
11. NaidooI, RoperC (2013) Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol 29: 505–515.
12. GonzálezR, Mombo-NgomaG, OuédraogoS, KakolwaMA, AbdullaS, et al. (2014) Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med 11: e1001733.
13. GonzálezR, DesaiM, MaceteE, OumaP, KakolwaMA, et al. (2014) Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. PLoS Med 11: e1001735.
14. NostenF, VincentiM, SimpsonJ, YeiP, ThwaiKL, et al. (1999) The effects of mefloquine treatment in pregnancy. Clin Infect Dis 28: 808–815.
15. ter KuileFO, van EijkAM, FillerSJ (2007) Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297: 2603–2616.
16. KayentaoK, GarnerP, van EijkAM, NaidooI, RoperC, et al. (2013) Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 309: 594–604.
17. TagborH, BruceJ, AgboM, GreenwoodB, ChandramohanD (2010) Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. PLoS ONE 5: e14425.
18. Medicines for Malaria Venture (2014) Medicines for Malaria Venture (MMV) Annual report 2013. Geneva: WHO. Available: http://www.mmv.org/newsroom/publications/annual-report-2013 Accessed 15 August 2014.